← Eichor
Study identifier: NCT04990908 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit

Condition: Severe Infection · Severe Immune Deficiency  ·  Sponsor: University Hospital, Montpellier

PhaseN/A
Planned participants100
Who can joinAll sexes, 3 Months to 16 Years
Healthy volunteersNo

About this study

Severe infections in pediatric intensive care unit are not uncommon. Historically, the diagnosis of hereditary (primary) immune deficiency required a combination of recurrent clinical signs and biological stigmas. This paradigm is currently being questioned, and grows the hypothesis of a potential underlying genetic susceptibility in any severe infection. To date, the proportion of severe infections explained by an underlying immune deficiency is unknown. The aim of this prospective study is to assess the incidence of primary immune deficiencies in children with severe infection, regardless of their etiology.

This description comes directly from the study's public registry record.

Talk to the study team

Eric JEZIORSKI  ·  04 67 33 57 98  ·  e-jeziorski@chu-montpellier.fr

Always discuss trial participation with your own doctor first.

Locations (1)

UhmontpellierMontpellier, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04990908